COLLAGEN DERIVED SERUM MARKERS IN CARCINOMA OF THE PROSTATE

被引:11
作者
RUDNICKI, M
JENSEN, LT
IVERSEN, P
机构
[1] UNIV COPENHAGEN, HERLEV HOSP, DEPT UROL, COPENHAGEN, DENMARK
[2] UNIV COPENHAGEN, HVIDOVRE HOSP, DEPT CLIN PHYSIOL, COPENHAGEN, DENMARK
[3] UNIV COPENHAGEN, HVIDOVRE HOSP, DEPT RHEUMATOL, COPENHAGEN, DENMARK
来源
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY | 1995年 / 29卷 / 03期
关键词
PROSTATIC CANCER; COLLAGEN; PSA;
D O I
10.3109/00365599509180582
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Three new collagen markers deriving from the collagenous matrix, e.g. carboxyterminal propeptide of type I procollagen (PICP), carboxyterminal pyridinoline cross-linked telopeptide of type I collagen (ICTP), and aminoterminal propeptide of type III procollagen (PIIINP) were used for the diagnose of prostatic bone metastases. Blood samples were obtained prior to biopsy or TURF. Serum PICP, PIIINP and ICTP were measured with commercial available RIAs and PSA by IRMA. Serum PSA was increased in patients with local prostatic cancer compared with patients with hyperplasia (p < 0.05). The level of PIIINP, ICTP, and PICP did not differ between these two groups. In patients with metastatic prostatic cancer all five markers were increased compared to measured in patients with localized (p < 0.0001). All variables showed a significant positive relationship with alkaline phosphatase. The sensitivity ranged from 0.53 to 0.62 and specificity from 0.91 to 0.95. The sensitivity for alkaline phosphatase and PSA was 0.69 and 0.66 and specificity 0.91 and 0.68, respectively.
引用
收藏
页码:317 / 321
页数:5
相关论文
共 24 条
[1]   OSTEOCALCIN - IS IT A USEFUL MARKER OF BONE METASTASIS AND RESPONSE TO TREATMENT IN ADVANCED PROSTATE-CANCER [J].
ARAI, Y ;
TAKEUCHI, H ;
OISHI, K ;
YOSHIDA, O .
PROSTATE, 1992, 20 (03) :169-177
[2]  
BEGG CB, 1986, CRC CRIT R MED INFOR, V1, P1
[3]   MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER [J].
CATALONA, WJ ;
SMITH, DS ;
RATLIFF, TL ;
DODDS, KM ;
COPLEN, DE ;
YUAN, JJJ ;
PETROS, JA ;
ANDRIOLE, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1156-1161
[4]   OSTEOCALCIN - A POTENTIAL MARKER OF METASTATIC BONE-DISEASE AND RESPONSE TO TREATMENT [J].
COLEMAN, RE ;
MASHITER, G ;
FOGELMAN, I ;
WHITAKER, KD ;
CALEFFI, M ;
MOSS, DW ;
RUBENS, RD .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (07) :1211-1217
[5]  
COOPER EH, 1990, CANCER, V66, P1025
[6]  
COOPER EH, 1992, CANCER-AM CANCER SOC, V70, P225, DOI 10.1002/1097-0142(19920701)70:1+<225::AID-CNCR2820701309>3.0.CO
[7]  
2-V
[8]  
CROB JC, 1988, EUR UROL, V15, P1993
[9]   MULTIVARIATE-ANALYSIS OF PROGNOSTIC FACTORS IN PATIENTS WITH ADVANCED PROSTATIC-CANCER - RESULTS FROM 2 EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER TRIALS [J].
DEVOOGT, HJ ;
SUCIU, S ;
SYLVESTER, R ;
PAVONEMACALUSO, M ;
SMITH, PH ;
DEPAUW, M .
JOURNAL OF UROLOGY, 1989, 141 (04) :883-888
[10]   THE CARBOXY-TERMINAL PROPEPTIDE OF TYPE-I PROCOLLAGEN IN SERUM AS A MARKER OF BONE-FORMATION - THE EFFECT OF NANDROLONE DECANOATE AND FEMALE SEX-HORMONES [J].
HASSAGER, C ;
JENSEN, LT ;
JOHANSEN, JS ;
RIIS, BJ ;
MELKKO, J ;
PODENPHANT, J ;
RISTELI, L ;
CHRISTIANSEN, C ;
RISTELI, J .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1991, 40 (02) :205-208